Drug Profile
Research programme: monoclonal antibody therapeutics - Chinook Therapeutics
Latest Information Update: 18 Aug 2023
Price :
$50
*
At a glance
- Originator Aduro BioTech
- Developer Sairopa
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD27 antigen inhibitors; CD70 antigen inhibitors; Programmed cell death-1 receptor antagonists; SIRPA protein inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
- 04 Jan 2023 Preclinical development is ongoing in Cancer in USA (Parenteral) (Sairopa pipeline, January 2023)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)